Praxis Precision Medicines (PRAX) Income from Continuing Operations (2019 - 2026)

Praxis Precision Medicines' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 562092000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 641.16% year-over-year to 562092000.0 in Q1 2026; TTM through Mar 2026 was 1130654000.0, a 142.84% decrease from a year earlier, with the FY2025 full-year figure at 736134000.0, down 75.91% from the prior year.
• Income from Continuing Operations slipped to 562092000.0 in Q1 2026 per PRAX's latest filing, from 403644000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 25738000.0 in Q3 2023 and bottomed at 562092000.0 in Q1 2026.
• The 5-year median for Income from Continuing Operations is 75840000.0 (2025), against an average of 137170058.82.
• Across the five-year window, Income from Continuing Operations surged 54.43% in 2023 and plunged 641.16% in 2026, its largest moves.
• Year by year, Income from Continuing Operations stood at 184066000.0 in 2022, then retreated by 13.17% to 208306000.0 in 2023, then sank by 35.5% to 282256000.0 in 2024, then slumped by 43.01% to 403644000.0 in 2025, then slumped by 39.25% to 562092000.0 in 2026.
• Per Business Quant, the three latest PRAX Income from Continuing Operations figures stand at 562092000.0 (Q1 2026), 403644000.0 (Q4 2025), and 87021000.0 (Q3 2025).